Armata Pharmaceuticals Receives FDA Fast Track Designation for AP-SA02
Armata Pharmaceuticals Inc. (NYSE:ARMP) received a significant regulatory milestone with the U.S. Food and Drug Administration granting Fast Track Designation to its drug candidate, AP-SA02. This paves the way for expedited review processes and supports the company's plans for Phase 3 trials later this year.
Tickers: $ARMP
Topics: biotech clinical_trials fda pharmaceuticals